Abstract:
Dengue virus is a human pathogen that infects roughly 390 million people each year, with a quarter
of them developing clinical symptoms. Although progress has been made in understanding the
biology of dengue fever, there is still no licensed vaccine or antiviral medication available. There
is yet no effective antidote for this virus. Patients' treatment is limited to symptomatic relief and
Care that is supportive. As a result, the discovery of dengue treatments is critical. This The focus
of this review is on the few compounds that have been tested in dengue virus patients: Balapiravir,
chloroquine, lovastatin, prednisolone, and celgosivir are some of the drugs used to treat HIV.
Balapiravir was expected that the medication would also be effective against DENV because the
RdRp of DENV and HCV are comparable. The lessons that these have taught us Clinical trials can
be extremely useful in the development of future trials for the dengue virus's next generation
inhibitors.
